Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion

被引:107
作者
Arora, P. [1 ]
Cuevas, B. D. [1 ]
Russo, A. [1 ]
Johnson, G. L. [1 ]
Trejo, J. [1 ]
机构
[1] Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA
关键词
thrombin; GPCR; metalloprotease; MDA-MB-231; g protein;
D O I
10.1038/onc.2008.84
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hyperactivation of ErbB signaling is implicated in metastatic breast cancer. However, the mechanisms that cause dysregulated ErbB signaling and promote breast carcinoma cell invasion remain poorly understood. One pathway leading to ErbB activation that remains unexplored in breast carcinoma cell invasion involves transactivation by G-protein-coupled receptors (GPCRs). Protease-activated receptor-1 (PAR1), a GPCR activated by extracellular proteases, is overexpressed in invasive breast cancer. PAR1 is also proposed to function in breast cancer invasion and metastasis, but how PAR1 contributes to these processes is not known. In this study, we report that proteolytic activation of PAR1 by thrombin induces persistent transactivation of EGFR and ErbB2/HER2 in invasive breast carcinoma, but not in normal mammary epithelial cells. PAR1-stimulated EGFR and ErbB2 transactivation leads to prolonged extracellular signal-regulated kinase-1 and -2 signaling and promotes breast carcinoma cell invasion. We also show that PAR1 signaling through G alpha(i/o) and metalloprotease activity is critical for ErbB transactivation and cellular invasion. Finally, we demonstrate that PAR1 expression in invasive breast carcinoma is essential for tumor growth in vivo assessed by mammary fat pad xenografts. These studies reveal a critical role for PAR1, a receptor activated by tumor-generated proteases, in hyperactivation of ErbB signaling that promotes breast carcinoma cell invasion.
引用
收藏
页码:4434 / 4445
页数:12
相关论文
共 32 条
  • [1] Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer
    Arora, Puneeta
    Ricks, Tiffany K.
    Trejo, JoAnn
    [J]. JOURNAL OF CELL SCIENCE, 2007, 120 (06) : 921 - 928
  • [2] Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
    Asakura, M
    Kitakaze, M
    Takashima, S
    Liao, Y
    Ishikura, F
    Yoshinaka, T
    Ohmoto, H
    Node, K
    Yoshino, K
    Ishiguro, H
    Asanuma, H
    Sanada, S
    Matsumura, Y
    Takeda, H
    Beppu, S
    Tada, M
    Hori, M
    Higashiyama, S
    [J]. NATURE MEDICINE, 2002, 8 (01) : 35 - 40
  • [3] Bergmann S, 2006, ONCOL REP, V15, P889
  • [4] PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells
    Boire, A
    Covic, L
    Agarwal, A
    Jacques, S
    Sherifl, S
    Kuliopulos, A
    [J]. CELL, 2005, 120 (03) : 303 - 313
  • [5] Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion
    Booden, MA
    Eckert, LB
    Der, CJ
    Trejo, J
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (05) : 1990 - 1999
  • [6] TACE is required for the activation of the EGFR by TGF-α in tumors
    Borrell-Pagès, M
    Rojo, F
    Albanell, J
    Baselga, J
    Arribas, J
    [J]. EMBO JOURNAL, 2003, 22 (05) : 1114 - 1124
  • [7] An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors
    Burgess, AW
    Cho, HS
    Eigenbrot, C
    Ferguson, KM
    Garrett, TPJ
    Leahy, DJ
    Lemmon, MA
    Sliwkowski, MX
    Ward, CW
    Yokoyama, S
    [J]. MOLECULAR CELL, 2003, 12 (03) : 541 - 552
  • [8] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
    Cobleigh, MA
    Vogel, CL
    Tripathy, D
    Robert, NJ
    Scholl, S
    Fehrenbacher, L
    Wolter, JM
    Paton, V
    Shak, S
    Lieberman, G
    Slamon, DJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2639 - 2648
  • [9] Darmoul D, 2004, MOL CANCER RES, V2, P514
  • [10] Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors
    Daub, H
    Weiss, FU
    Wallasch, C
    Ullrich, A
    [J]. NATURE, 1996, 379 (6565) : 557 - 560